TB-500 (30 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

TB-500 is a synthetic peptide corresponding to the active N-terminal fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published preclinical and analytical work, not a recommendation for use in humans or animals.

For a 30 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that concentration, every 0.10 mL drawn on a U-100 insulin syringe equals 10 units and delivers 1 mg (1000 mcg) of material, so a 500 mcg measurement lands at exactly 5 units (0.05 mL) and the arithmetic stays clean across every titration step.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow ramp commonly modelled in the research literature, where the daily amount is stepped up every couple of weeks while tolerability at each level is confirmed before escalating.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, which helps avoid foaming.
3. Swirl or roll the vial gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Aggressive) Titration Schedule

The advanced schedule front-loads the protocol, opening at the 1 mg daily ceiling for a saturation phase before stepping down to a lower maintenance amount. It reaches steady state faster but uses more material in the early weeks.

Supplies Needed

• TB-500 vials (30 mg): ~2 vials for an 8-week run; ~3 vials for a 12-week run; ~4 vials for a 16-week run (one 30 mg fill lasts roughly six weeks at ~5 mg/week).
• Insulin syringes (U-100, 1 mL): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks (one fresh syringe per daily draw).
• Bacteriostatic water (10 mL): one bottle covers ~3 vials; two bottles for a 12–16 week run.
• Alcohol swabs: a 100-count box per ~8 weeks; two to three boxes for a 12–16 week schedule.

Protocol Overview

• Research goal: model angiogenesis, cell migration and tissue-repair pathways driven by thymosin β4 fragment activity.
• Schedule: once-daily subcutaneous administration in the published handling model.
• Dose band: 500 mcg–1 mg daily, averaging ~5 mg per week.
• Fill: 30 mg lyophilized, reconstituted to 10 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 500 mcg step and hold each level for the indicated window before escalating.
• Keep administration on a fixed daily cadence at roughly the same time for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• The 750 mcg–1 mg band captures most of the daily exposure seen in the repair-focused models.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light and moisture, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and do not freeze the solution; use within about four weeks (28 days) when reconstituted with bacteriostatic water. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Roll rather than shake when mixing, and rotate handling technique to keep the stopper intact.
• Split larger volumes if they exceed a single syringe’s capacity.
• Document each draw — date, volume, remaining material — for reproducibility.

How TB-500 Works

TB-500 corresponds to the N-terminal active region of thymosin beta-4, centred on the heptapeptide sequence Ac-LKKTETQ. Thymosin β4 is an actin-binding protein that regulates cell motility, and the isolated fragment is studied for its ability to promote angiogenesis (new blood-vessel formation), support cell migration into injured tissue, and accelerate the granulation and remodelling stages of wound healing. Some analytical work proposes that it behaves as a prodrug, cleaving to a shorter active metabolite that carries much of the biological signal. Because it is a small, water-soluble peptide, it disperses readily through tissue in the experimental models.

Reported Benefits & Side Effects

Benefits observed in research

• Accelerated wound closure and tissue repair attributed to enhanced angiogenesis and cell migration.
• Greater collagen deposition and shortened healing time at injury sites in preclinical models.
• Indirect anti-inflammatory and anti-fibrotic signals reported through thymosin pathways in animal studies.

Side effects reported

• Generally well tolerated in veterinary and animal studies, with occasional mild injection-site reactions.
• Possible transient redness or tenderness at the administration site.
• Human safety data is limited; no large-scale clinical trials have been completed.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let both air-dry completely.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily, then wait 5–10 seconds before withdrawing the needle.
• Rotate sites systematically within approved areas (abdomen, thighs, upper arms) to avoid lipohypertrophy, and dispose of sharps in an approved container.

References

Related Protocols